A5021890766- Gastric Cancer Management and Outcomes
- Inflammatory Bowel Disease
- Esophageal and GI Pathology
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Esophageal Cancer Research and Treatment
- Microscopic Colitis
- Liver Diseases and Immunity
- Gallbladder and Bile Duct Disorders
- Pregnancy and Medication Impact
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Helicobacter pylori-related gastroenterology studies
- Lipid metabolism and disorders
- Biliary and Gastrointestinal Fistulas
- Gastrointestinal disorders and treatments
- Phytase and its Applications
- Palliative Care and End-of-Life Issues
- Health and Wellbeing Research
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Biosimilars and Bioanalytical Methods
- Pharmacological Effects of Natural Compounds
- Pediatric Hepatobiliary Diseases and Treatments
Thomas Jefferson University Hospital
2024
AdventHealth Orlando
2023-2024
University of Toronto
2022
McGill University
2017-2021
INTRODUCTION: We aimed to evaluate the real-world effectiveness and safety of tofacitinib for treatment ulcerative colitis (UC). METHODS: REMIT-UC is a Canadian multicenter cohort study. Standardized data collection was performed on 334 consecutive adult outpatients with UC treated tofacitinib. The primary outcomes were achievement clinical endoscopic remission. Safety reported using incidence rates (events/100 patient-years exposure). A multivariable Cox proportional hazards model used...
Hybrid endoscopic submucosal dissection (H-ESD), which utilizes ESD knife along with snare-based resection, has been developed to overcome the technical complexity of conventional (C-ESD). The aim this study was compare therapeutic outcomes H-ESD vs C-ESD for nonpedunculated colorectal lesions ≥20 mm in size.
The isolation of asymptomatic Clostridium difficile (CD) carriers may decrease the incidence hospital-associated C. infections (CDI), but its impact on precaution needs is unknown.A time series analysis was conducted to investigate isolating CD burden precautions from 2008 2016 in a Canadian hospital. To account for changes infection control policies, divided into 3 intervention periods: period 1 (2008-2011), patients with CDI until symptom resolution; 2 (2011-2013), discharge; and...
Abstract Background A significant proportion of patients do not respond to therapy for moderate severe ulcerative colitis (UC), including thiopurines, glucocorticoids, and antagonists tumour necrosis factor-a integrin. Tofacitinib, a Janus Kinase inhibitor, has emerged as an efficacious safe treatment colitis. However, data on its real-life efficacy remains sparse. Methods We aimed assess the rate clinical response remission at 3 6 months after tofacitinib initiation. Secondary endpoints...
Giant cell hepatitis (GCH) is a rare entity in adults that characterized by large multinucleated hepatocyte formation and parenchymal inflammation. We present case of acute liver failure 33-year-old woman secondary to autoimmune (AIH). A biopsy revealed submassive necrosis consistent with GCH. conducted literature review 187 reported cases post-infantile GCH adults. AIH was the most commonly cause GCH, but associated wide spectrum etiologies, including infections, rheumatological diseases,...
ABSTRACT Pseudopolyps are benign lesions without malignant potential and typically do not require biopsy or excision. We describe a 68-year-old man with ulcerative colitis found to have multiple large bridging pseudopolyps. Repeated colonoscopies extensive biopsies revealed ulcerated lesion previously hidden within the The pathology of was consistent low-grade adenocarcinoma invasion into muscularis propria. This demonstrates that pseudopolyps, although benign, can obscure other potential....
Abstract Background A significant proportion of patients with moderate to severe ulcerative colitis (UC) do not respond therapy, which includes thiopurines, glucocorticoids, and antagonists tumour necrosis factor-α integrin. Tofacitinib, a Janus Kinase inhibitor, has emerged as an efficacious safe treatment for colitis. However, it is known if this efficacy translates into real-life effectiveness in regular clinical practice. Aims We aimed assess the rate response remission at 3 6 months...
Introduction: Crohn’s Disease (CD) patients are twice as likely compared to controls develop nonalcoholic fatty liver disease (NAFLD) leading increased risk of cardiometabolic complications. Given this, we developed the first clinical screening tool for NAFLD in CD, Clinical Predictor CD (CPN-CD) which uses readily accessible laboratory and parameters. We have demonstrated CPN-CD outperforms Hepatic Steatosis Index detecting an internal cohort. Here performed a multicenter analysis...